X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (820) 820
Publication (53) 53
Book / eBook (7) 7
Book Review (7) 7
Conference Proceeding (3) 3
Magazine Article (3) 3
Book Chapter (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (618) 618
male (396) 396
female (335) 335
hydrazines - adverse effects (322) 322
hydrazines - therapeutic use (314) 314
middle aged (268) 268
index medicus (256) 256
adult (234) 234
animals (229) 229
aged (207) 207
hydrazines - administration & dosage (147) 147
hydrazines - pharmacology (146) 146
benzoates - therapeutic use (138) 138
pyrazoles - therapeutic use (138) 138
pyrazoles - adverse effects (121) 121
parkinson disease - drug therapy (120) 120
benzoates - adverse effects (119) 119
receptors, thrombopoietin - agonists (105) 105
purpura, thrombocytopenic, idiopathic - drug therapy (99) 99
eltrombopag (95) 95
rats (92) 92
hematology (90) 90
pharmacology & pharmacy (80) 80
hydrazine (76) 76
oncology (76) 76
thrombocytopenia (76) 76
time factors (73) 73
clinical trials as topic (72) 72
treatment outcome (72) 72
hydrazines (71) 71
dose-response relationship, drug (65) 65
levodopa - adverse effects (65) 65
platelet count (65) 65
benzoates - administration & dosage (61) 61
pyrazoles - administration & dosage (61) 61
mice (59) 59
receptors, fc - therapeutic use (59) 59
thrombocytopenia - drug therapy (58) 58
drug therapy, combination (56) 56
levodopa - therapeutic use (54) 54
thrombopoietin (53) 53
adolescent (52) 52
thrombopoietin - therapeutic use (52) 52
dihydroxyphenylalanine - adverse effects (51) 51
aged, 80 and over (48) 48
antineoplastic agents - adverse effects (48) 48
recombinant fusion proteins - therapeutic use (47) 47
carbidopa - therapeutic use (45) 45
dihydroxyphenylalanine - therapeutic use (45) 45
medicine, general & internal (45) 45
carbidopa - adverse effects (44) 44
romiplostim (44) 44
cancer (43) 43
antineoplastic agents - therapeutic use (42) 42
double-blind (42) 42
management (41) 41
analysis (40) 40
toxicology (40) 40
chronic disease (39) 39
drug therapy (39) 39
hydrazines - chemistry (39) 39
isoniazid - adverse effects (39) 39
purpura (39) 39
safety (38) 38
thrombopoietin - adverse effects (38) 38
benserazide - therapeutic use (37) 37
efficacy (37) 37
hydrazines - pharmacokinetics (37) 37
recombinant fusion proteins - adverse effects (36) 36
benserazide - adverse effects (35) 35
drug combinations (35) 35
levodopa - administration & dosage (35) 35
young adult (35) 35
administration, oral (34) 34
dihydroxyphenylalanine - administration & dosage (34) 34
health aspects (33) 33
hydrazines - toxicity (33) 33
immune thrombocytopenia (33) 33
care and treatment (32) 32
drug synergism (32) 32
neoplasms - drug therapy (32) 32
pyrazoles - pharmacology (32) 32
benzoates - pharmacology (29) 29
research (29) 29
double-blind method (28) 28
purpura, thrombocytopenic, idiopathic - blood (28) 28
risk factors (28) 28
carbidopa - administration & dosage (27) 27
chemotherapy (27) 27
drug evaluation (27) 27
isoniazid (27) 27
pharmacokinetics (27) 27
platelets (26) 26
randomized controlled trials as topic (26) 26
toxicity (26) 26
aromatic amino acid decarboxylase inhibitors (25) 25
hydrazines - metabolism (25) 25
itp (25) 25
abridged index medicus (24) 24
child (24) 24
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (709) 709
German (32) 32
French (22) 22
Spanish (17) 17
Japanese (13) 13
Russian (12) 12
Italian (9) 9
Polish (6) 6
Chinese (3) 3
Danish (2) 2
Portuguese (2) 2
Swedish (2) 2
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0198184
Background Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Medical services | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
Blood, ISSN 0006-4971, 03/2014, Volume 123, Issue 12, pp. 1818 - 1825
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 108 - 116
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1540 - 1550
Journal Article
by Saleh, Mansoor N and Bussel, James B and Cheng, Gregory and Meyer, Oliver and Bailey, Christine K and Arning, Michael and Brainsky, Anes and Chong, B and Pidcock, M and Pabinger-Fasching, I and Olney, H and Arnold, D and Assouline, S and Shen, Z and Yang, R and Sun, A and Mayer, J and Pohlreichova, V and Hlusi, A and Marcher, C and Nousiainen, T and Godeau, B and Cheze, S and Viallard, J and Ganser, A and Matzdorff, A and Salama, A and Schroeder, D and von Depka Prondzinski, M and Hiller, E and Rummel, M and Anagnostopoulos, A and Poziopoulos, C and Wong, R and Fabris, F and Ciceri, F and Angelini, F and Vianelli, N and Kim, B and Novotný, V and Biemond, B. J and Schipperus, M. R and Wittebol, S and Blacklock, H and Simpson, D and Ganly, P and Doocey, R and Shamsi, T and Aziz, Z and Murillo, S and Ulloa, V and Kloczko, J and Dmoszynska, A and Robak, T and Kuliczkowski, K and Homenda, W and Calbecka, M and Antonio Stoia, R and Vladareanu, A and Kovaleva, L and Rukavitsyn, O and Domnikova, N and Abdulkadyrov, K and Palasthy, S and Reimana, J. A and Lazur, J and Escudero Soto, A and Besalduch, J and Páramo Fernández, J and Gerosa, S and Ribera Santasusana, J and Perez Crespo, S and Alonso, A and Pascual Izquierdo, C and Wadenvik, H and Lerner, R and Tsay, W and Rojnuckarin, P and Sirijerachai, C and Meddeb, B and M'Sadek, F and Khelif, A and Davies, S and Nokes, T and Grech, H and Al-Ismail, S and Scully, M and Martlew, V and Masliak, Z and Kaplan, P and Cosgriff, T and Giudice, R and Hon, J and Kuriakose, P and Liebman, H and Flynn, P and Smith, D and Fogarty, P and Quick, D and de Oliveira, M and ... and EXTEND Study Grp and EXTEND Study Group
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 3, pp. 537 - 545
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 6, pp. 10748 - 10759
Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients... 
Ixazomib | Daratumumab | Elotuzumab | Multiple myeloma | multiple myeloma | elotuzumab | OPEN-LABEL | T-CELL THERAPY | BORTEZOMIB | CELL BIOLOGY | IMMUNE-SYSTEM | ANTIBODIES TARGETING CD38 | daratumumab | MONOCLONAL-ANTIBODIES | ORAL PROTEASOME INHIBITOR | PD-1 | Glycine - analogs & derivatives | Glycine - therapeutic use | Triazoles - adverse effects | Glycine - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Multiple Myeloma - immunology | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Thiadiazoles - adverse effects | Multiple Myeloma - drug therapy | Thiadiazoles - therapeutic use | Multiple Myeloma - enzymology | Triazoles - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Congresses as Topic | Hydrazines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Treatment Outcome | Proteasome Inhibitors - adverse effects | Proteasome Inhibitors - therapeutic use | Antineoplastic Agents, Immunological - adverse effects | Multiple Myeloma - pathology | Signal Transduction - drug effects | Antineoplastic Agents, Immunological - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Boron Compounds - adverse effects | Boron Compounds - therapeutic use | Hydrazines - adverse effects
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 9, pp. 859 - 866
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 22, pp. 2237 - 2247
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 1, pp. 11 - 19
Journal Article